Dermatology

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

Yosipovitch spoke in this interview about the clinical trials leading up to the FDA approval of his nemolizumab for patients with prurigo nodularis.

In this interview, Yosipovitch discusses his team’s findings on nemolizumab and the significance of the drug’s FDA approval for those with prurigo nodularis.

In an interview, Raj Chovatiya, MD, PhD, highlights the effectiveness of lebrikizumab, providing stable improvements by week 52.

Withdrawal of baricitinib in severe alopecia areata led to hair loss in 80% of patients, highlighting the need for ongoing therapy to maintain regrowth.

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

Despite these findings, additional research may be necessary to evaluate emerging therapies and prognostic factors in the management of chronic actinic dermatitis.

In this interview, Chovatiya spoke with the editorial team about the global prevalence findings on patients with seborrheic dermatitis and their implications.

Atopic dermatitis increases stress, depression, anxiety, and suicidal ideation, affecting patients' mental health, a recent study found.

Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.

New study highlights racial disparities in psoriasis management, revealing non-Hispanic Black patients are twice as likely to receive a skin biopsy compared to White counterparts.

These findings were the result of an active-comparator study, highlighting the benefits of betamethasone versus tacrolimus among patients with eczema.

These data from the United Arab Emirates provide insight into the comorbidities, epidemiology, patterns of treatment, and use of healthcare resources of alopecia areata patients.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.

In this episode of Crisis Point, 3 experts in dermatology discuss ways in which those in the field are working to improve visibility of diverse skin types within dermatology education.

These data indicate the need for future analyses of possible chronic urticaria activity biomarkers, as well as other elements of patient response to omalizumab treatment.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

Following this pooled analysis, there may be a need for additional research conducted to identify other targets for achievement of optimal repigmentation.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.